Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
General22 hours agoMitch Marsh inspires Australia to three-wicket win over New Zealand in third T20I
-
General21 hours agoNothing to see here *wink wink*
-
General20 hours agoNewcastle Jets defeat semi-professional Heidelberg United 3-1 to lift first Australia Cup
-
General23 hours agoThis isn’t progress, it’s punishment